In addition to requests for double-digit premium increases, Blue Cross Blue Shield of Vermont is also cutting back on coverage of popular weight-loss drugs on some plans.

The top reasons weight loss supplements fail and why most solutions don't address both day and night fat-burning cycles; How PhenQ works as a powerful daytime fat burner to help r ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Fact checked by Nick Blackmer Tirzepatide and semaglutide, the ingredients in popular weight loss drugs, can both cause side ...

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for the safe and ...

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Trump is benefiting from the medical infrastructure the government has built up, while simultaneously destroying that infrastructure for everyone else.

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Pending regulatory authorization, Fractyl expects to dose the first patients with RJVA-001 and report preliminary data in 2026, which the Company believes could lead to a potentially first-in-class, ...

The NHS has been urged to accelerate the rollout of weight loss drugs to “many millions” of people, as experts hailed the start of a “golden age” of anti-obesity treatments. A raft of studies ...